Life Science Investing PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale 17 October
Life Science Investing PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease 16 October
Life Science Investing PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505 NDA Filings 15 October
